iBio (NASDAQ:IBIO) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of iBio (NASDAQ:IBIO) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities research analysts also recently issued research reports about the stock. JonesTrading assumed coverage on shares of iBio in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Friday, March 27th. Finally, Chardan Capital reissued a “buy” rating and issued a $5.00 target price on shares of iBio in a research report on Thursday, April 9th. Three analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, iBio presently has an average rating of “Buy” and an average target price of $4.75.

iBio Trading Down 5.8%

Shares of IBIO stock opened at $1.47 on Friday. The company’s fifty day simple moving average is $2.00 and its 200-day simple moving average is $1.95. iBio has a 52 week low of $0.56 and a 52 week high of $3.82. The company has a market cap of $53.13 million, a PE ratio of -2.53 and a beta of 1.23.

iBio (NASDAQ:IBIO) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Equities research analysts expect that iBio will post -0.36 EPS for the current fiscal year.

Insider Transactions at iBio

In related news, CFO Felipe Duran purchased 24,835 shares of iBio stock in a transaction dated Thursday, March 19th. The stock was bought at an average cost of $2.02 per share, with a total value of $50,166.70. Following the purchase, the chief financial officer owned 35,974 shares in the company, valued at approximately $72,667.48. The trade was a 222.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.75% of the stock is owned by insiders.

Institutional Trading of iBio

A number of institutional investors have recently made changes to their positions in IBIO. Jane Street Group LLC bought a new stake in shares of iBio in the 4th quarter worth approximately $204,000. Boothbay Fund Management LLC raised its holdings in shares of iBio by 10.9% in the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock worth $146,000 after purchasing an additional 17,414 shares in the last quarter. State Street Corp raised its holdings in shares of iBio by 116.3% in the 4th quarter. State Street Corp now owns 72,899 shares of the company’s stock worth $141,000 after purchasing an additional 39,200 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of iBio in the 4th quarter worth approximately $76,000. Finally, Susquehanna International Group LLP bought a new stake in shares of iBio in the 3rd quarter worth approximately $37,000. 7.90% of the stock is owned by institutional investors and hedge funds.

Key iBio News

Here are the key news stories impacting iBio this week:

• Positive Sentiment: Brookline Capital Markets raised its earnings estimates across several periods, including FY2026 and FY2027, signaling improved expectations for iBio’s profitability trend. The firm now sees smaller losses than before, which can be viewed as a mild positive for sentiment.
• Positive Sentiment: Lifesci Capital also nudged up its Q4 2026 EPS estimate and kept its later-period forecasts intact, adding to the view that analysts are becoming slightly less bearish on near-term losses.
• Neutral Sentiment: Multiple analyst reports published on May 13 mostly reiterated negative EPS forecasts, with iBio still expected to post losses in upcoming quarters and for the full year.
• Negative Sentiment: Wall Street Zen downgraded iBio to Sell, which likely pressured shares by reinforcing concerns about the stock’s outlook despite the more optimistic estimate revisions.
• Neutral Sentiment: A separate article said investors may not be very worried about iBio’s cash burn, which could help temper concerns about dilution or liquidity, but it does not appear to be the main driver today.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.